Dicerna Pharma (DRNA) Misses Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Dicerna Pharmaceuticals (DRNA) PT Raised to $10 at H.C. Wainwright on 3Q Report; 'Landmark Deal With BI on NASH Target Validates GalXC Platform'
November 3, 2017 7:53 AM EDTH.C. Wainwright raised its price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $10.00 (from $6.00) while maintaining a Buy rating, following news of a research collaboration and license agreement, as the company reported third quarter earnings report.
Analyst Ed Arce notes a positive outlook... More
